Doreen Busingye

Doreen Busingye

Auto-generated profile, based on publicly available information

Doreen Busingye

Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2019 in International Journal of Epidemiology
Verified
Journal Article
Open access
DBDoreen Busingye
Doreen Busingye
CGChristopher Gianacas
Christopher Gianacas
APAllan Pollack
Allan Pollack
KCKendal Chidwick
Kendal Chidwick
AMAlistair Merrifield
Alistair Merrifield
NSNigel Stocks
Nigel Stocks

26 May 2014 in International Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
DBDoreen Busingye
Doreen Busingye
SASimin Arabshahi
Simin Arabshahi
ASAsvini K Subasinghe
Asvini K Subasinghe
RERoger G Evans
Roger G Evans
MRMichaela A Riddell
Michaela A Riddell
ATAmanda G Thrift
Amanda G Thrift
Background: Of the 1 billion people with hypertension globally, two-thirds reside in low- and middle-income countries (LMICs). The risk of hypertension in LMICs is thought to be positively associated with socioeconomic status (SES). However, recent studies have provided data inconsistent with this concept. Thus, we assessed the association between SES and hypertension in rural populations of LMICs. Further, we explored whether this association differs according to geographical region.

27 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DBDoreen Busingye
Doreen Busingye
APAllan Pollack
Allan Pollack
KCKendal Chidwick
Kendal Chidwick
The burden of inflammatory bowel disease (IBD) in Australia is increasing but national data about the current prevalence are limited. We aimed to estimate the prevalence of IBD (including Crohn’s disease, ulcerative colitis and unspecified IBD) as well as Crohn’s disease and ulcerative colitis separately in a general practice population in Australia. We also assessed risk factors associated with Crohn’s disease and ulcerative colitis. We conducted a cross-sectional study using data from MedicineInsight, a national database of general practice electronic health records, from 1 July 2017 to 30 June 2019. The prevalence of IBD was calculated and stratified by sociodemographic characteristics. Logistic regression analysis was conducted to assess risk factors associated with Crohn’s disease and ulcerative colitis. The study comprised 2,428,461 regular patients from 481 practices. The estimated crude prevalence of IBD was 653 per 100,000 patients; Crohn’s disease was 306 per 100,000 and ulcerative colitis was 334 per 100,000. Males were independently associated with a lower risk of Crohn’s disease (OR: 0.86; 95% CI: 0.81, 0.90) but a greater risk of ulcerative colitis (OR: 1.12; 95% CI: 1.06, 1.17) than females. Compared to non-smokers, patients who were current smokers were associated with a greater risk of Crohn’s disease (OR: 1.13; 95% CI: 1.04, 1.23) but a lower risk of ulcerative colitis (OR: 0.52; 95% CI: 0.47, 0.57). Other factors positively associated with both Crohn’s disease and ulcerative colitis were age (≥ 25 years), non-Indigenous status and socioeconomic advantage. Our findings provide a current estimate of the prevalence of IBD, Crohn’s disease and ulcerative colitis in a large national general practice population in Australia and an assessment of the factors associated with Crohn’s disease and ulcerative colitis. These data can assist in estimating the health burden and costs, and planning for health services.

10 November 2020 in BJGP Open
Verified
Journal Article
Open access
PDF file
ASAndrea L Schaffer
Andrea L Schaffer
DBDoreen Busingye
Doreen Busingye
KCKendal Chidwick
Kendal Chidwick
JBJonathan Brett
Jonathan Brett
SBSuzanne Blogg
Suzanne Blogg
Background: In 2013 pregabalin was subsidised by Australia’s Pharmaceutical Benefits Scheme (PBS) for neuropathic pain. Since the subsidy, pregabalin prescribing has been increasing in Australia and so has related harm. There are concerns it is being prescribed for indications other than neuropathic pain, which have little evidence of efficacy.Aim: To describe pregabalin prescribing in Australian general practice.Design & setting: A cross-sectional study of patients attending 445 general practice sites in the national MedicineInsight database from March 2012–February 2018.Method: The following aspects were calculated: the proportion of prescriptions that were for pregabalin per year; the prevalence of pain conditions in patients prescribed pregabalin; and same-day prescribing of pregabalin with opioids or benzodiazepines.Results: Prescribing increased from 13 per 10 000 to 104 per 10 000 prescriptions between 2012–2013 and 2017–2018. A total of 1 891 623 patients were identified of whom 114 123 (6.0%) were prescribed pregabalin; 49.7% (n = 56 772) had a recorded diagnosis of neuropathic pain. Among people prescribed pregabalin without a recorded diagnosis of neuropathic pain, 43.5% (n = 24 927) had a diagnosis of back problems, 8.8% (n = 5073) chronic pain, and 26.4% (n = 30 146) had no pain diagnosis. Pregabalin was prescribed the same day as an opioid to 38.1% of patients (95% confidence interval [CI] = 37.1% to 39.1%) and a benzodiazepine to 13.1% of patients (95% CI = 12.5% to 13.7%). Patients with a diagnosis of chronic pain had the highest rate of same-day prescribing of pregabalin with an opioid (70.4%, 95% CI = 68.9% to 71.9%) or a benzodiazepine (25.8%, 95% CI = 24.2% to 27.4%)Conclusion: Substantial increases in pregabalin prescribing were identified in Australian general practice, but only half of patients had a neuropathic pain diagnosis recorded, the only approved indication for subsidy. High rates of same-day prescribing with opioids and benzodiazepines may put patients at increased risk of harm.

1 December 2011 in Spatial and Spatio-temporal Epidemiology
Verified
Journal Article
Closed access
DBDoreen Busingye
Doreen Busingye
APAshley Pedigo
Ashley Pedigo
AOAgricola Odoi
Agricola Odoi

28 February 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMonique Kilkenny
Monique Kilkenny
LDLibby Dunstan
Libby Dunstan
DBDoreen Busingye
Doreen Busingye
TPTara Purvis
Tara Purvis
MRMegan Reyneke
Megan Reyneke
DCDominique A. Cadilhac
Dominique A. Cadilhac
There is limited evidence on whether having pre-existing cardiovascular disease (CVD) or risk factors for CVD such as diabetes, ensures greater knowledge of risk factors important for motivating preventative behaviours. Our objective was to compare knowledge among the Australian public participating in a health check program and their risk status. Data from the Stroke Foundation ‘Know your numbers’ program were used. Staff in community pharmacies provided opportunistic health checks (measurement of blood pressure and diabetes risk assessment) among their customers. Participants were categorised: 1) CVD ± risk of CVD: history of stroke, heart disease or kidney disease, and may have risk factors; 2) risk of CVD only: reported having high blood pressure, high cholesterol, diabetes or atrial fibrillation; and 3) CVD risk free (no CVD or risk of CVD). Multivariable logistic regression analyses were performed including adjustment for age and sex. Among 4,647 participants, 12% had CVD (55% male, 85% aged 55+ years), 47% were at risk of CVD (40% male, 72% 55+ years) and 41% were CVD risk free (33% male, 27% 55+ years). Participants with CVD (OR: 0.66; 95% CI: 0.55, 0.80) or risk factors for CVD (OR: 0.65; 95% CI: 0.57, 0.73) had poorer knowledge of the risk factors for diabetes/CVD compared to those who were CVD risk free. After adjustment, only participants with risk factors for CVD (OR: 0.80; 95% CI: 0.69, 0.93) had poorer knowledge. Older participants (55+ years) and men had poorer knowledge of diabetes/CVD risk factors and complications of diabetes. Participants with poorer knowledge of risk factors were older, more often male or were at risk of developing CVD compared with those who were CVD risk free. Health education in these high risk groups should be a priority, as diabetes and CVD are increasing in prevalence throughout the world.